Preman Kumarathurai, MD PhD MSc

MD, PhD, MSc | Cardiologist at Odense University Hospital | Associate Editor for Cardiovascular Diabetology |

[Julie Hempel @jhempelheart]

❤️❤️ #ESCCongress2023 with colleagues from @CardResearchOuh❤️❤️

@MassarOmard @LouiLinde @pkumarathurai

#JoinForcesWithESC #ESCCongress #DCS_ESC23

[Aaysha Cader @aayshacader]

What an incredible day! 🎓
Graduated from @UniofOxford with this fabulous bunch : Inaugural cohort of the @Oxford_NDPH MSc in Clinical Trials! We made it, guys! 🙌

[Tor Biering-Sørensen, MD, MSc, MPH, PhD @TorBiering]

Dinner with my amazing classmates and the Godfather of randomized trials, Sir Richard Peto, at @UniofOxford

@pkumarathurai @BoldiKovacsMD @JulePinter @willkidney @FH_Verbrugge @aayshacader @cristina_gavina @escardio @CopCard @CIRL_DK @BiomedUCPH @koebenhavns_uni @Oxford_NDPH

[Aaysha Cader @aayshacader]

What a fantastic week with these wonderful people @Oxford_NDPH #MScClinicalTrials #AcademyESC @escardio

@DjawidHashemi @cristina_gavina @MLHandoko @FH_Verbrugge @A_FelixOliveira @TorBiering @Carlosomendivi1 @JulePinter @pkumarathurai @BoldiKovacsMD @PraveenRoyMD

[Tor Biering-Sørensen, MD, MSc, MPH, PhD @TorBiering]

The Godfather of randomized trials, Sir Richard Peto, giving an amazing talk about ‘Interpreting large-scale randomised evidence’ at the MSc in RCT’s at @UniofOxford

@FH_Verbrugge @BoldiKovacsMD @DjawidHashemi @aayshacader @pkumarathurai @RichardHaynes3 @CopCard @CIRL_DK

[Aaysha Cader @aayshacader]

Iconic slide on subgroup analyses with the icon himself! #RichardPeto #RCT #ISIS2 ♎♊

⭕ Fantastic first day @Oxford_NDPH #MScClinicalTrials

@DjawidHashemi @cristina_gavina @BoldiKovacsMD @TorBiering @FH_Verbrugge @MLHandoko @JulePinter @pkumarathurai @PraveenRoyMD

[Preman Kumarathurai, MD PhD MSc @pkumarathurai]

@DjawidHashemi @berlinnovation @dhzberlin @ChariteBerlin @CardiacStats @dzhk_germany @YoungDZHK @YoungDgk Congrats 😊

[Preman Kumarathurai, MD PhD MSc @pkumarathurai]

@TorBiering Congratulations, my friend 👏😊

[European Society of Cardiology @escardio]

#EMPEROR-Preserved trial: empagliflozin reduces the risk of a composite of #cardiovascular death or hospitalisation for #heartfailure in patients with #HFpEF with or without #diabetes

#ESCCongress

[Muthu Vaduganathan @mvaduganathan]

#EMPERORPreserved Top Line 🔥
Empagliflozin ↓ risk of CVd+HF hosp in 5,988 pts HFpEF

Awaiting #ESC2021 LBCT together w #EMPERORPooled (n=9,718) across LVEF spectrum (primary EP of kidney events)

Bravo @JavedButler1 #StefanAnker @FaiezZANNAD @Filippatos

https://t.co/icBrADcv2d

[Daniel J Drucker @DanielJDrucker]

Beyond Heart Rate. Consistent lack of effect of GLP-1RA on diastolic function parameters in PPL with type 2 #diabetes and CAD https://t.co/n2dm7MWwEK

[Stephan Achenbach @Steph_Achenbach]

Important for us cardiologists to see the force behind this bleed in LV free wall rupture after STEMI. Thank you @ShariqShamimMD and thank you #cardiotwitter for the opportunity to share such insight.

@escardio @beatscaduk @SCAI @mirvatalasnag @Drroxmehran @mmamas1973

[The Lancet @TheLancet]

Today, three of the authors have retracted "Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis" Read the Retraction notice and statement from The Lancet https://t.co/pPNCJ3nO8n

[Henry Drysdale @HenryMDrysdale]

The @US_FDA authorised remdesivir for COVID-19 on the basis of 1 outcome from the NIAID trial. This outcome was switched, the trial is unpublished, and we have no good evidence remdesivir reduces mortality. Our piece for @CebmOxford @NDevito1 @JKAronson https://t.co/48vXkI00ju

[Preman Kumarathurai, MD PhD MSc @pkumarathurai]

Researcher promoting red meat, sugar failed to disclose industry ties—again https://t.co/wbfZC1onuv

[Gregg W. Stone MD @GreggWStone]

DAPA HF: 4744 pts w/HFrEF w/or w/o diabetes rand to SGLT2i dapaglifozin vs placebo. Med 18 mo FU. CV death, HF hosp or urgent HF visit reduced by 26%, p<0.0001. Sign decrease in CV death as well as HF events. All death decr. Benefits identical in pts w/& w/o DM. New Rx for HFrEF!

[American College of Cardiology @ACCinTouch]

The HUAWEI Heart study found continuous home monitoring w/ mobile health devices equipped w/ PPG technology could be a feasible approach for screening & early detection of #AFib in large populations. #ESCCongress #JACC https://t.co/IIVegp1oqc

[Preman Kumarathurai, MD PhD MSc @pkumarathurai]

Very cool navigation feature in the #ESCcongress2019 app

[Stephan Achenbach @Steph_Achenbach]

DAPA-HF trial at #ESCCongress: significant reduction of events in HFrEF patients by dapagliflozine. Half of the 5744 pts had diabetes, the others did not: same effect in both groups.
SGLT2 inhibitors just better diuretics or the "statins of HF"?
@escardio #cardiotwitter

[NowThis Impact @nowthisimpact]

Fox News tried coming after Denmark's social safety net. This Danish politician's retort was legendary.